Symbols / KALA $0.36 +24.16%
KALA Chart
About
KALA BIO, Inc. a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of therapies for rare and severe eye diseases. The company's lead product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects; and limbal stem cell deficiency and other rare corneal diseases. Its preclinical development product consists of KPI-014 for the treatment of rare inherited retinal diseases. The company was formerly known as Kala Pharmaceuticals, Inc. and changed its name to KALA BIO, Inc. in August 2023. KALA BIO, Inc. was incorporated in 2009 and is headquartered in Arlington, Massachusetts.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 332.54M |
| Enterprise Value | 11.84M | Income | -35.84M | Sales | — |
| Book/sh | -1.17 | Cash/sh | 2.57 | Dividend Yield | — |
| Payout | 0.00% | Employees | 38 | IPO | — |
| P/E | — | Forward P/E | -0.05 | PEG | — |
| P/S | — | P/B | -0.31 | P/C | — |
| EV/EBITDA | -0.29 | EV/Sales | — | Quick Ratio | 0.65 |
| Current Ratio | 0.74 | Debt/Eq | — | LT Debt/Eq | — |
| EPS (ttm) | -5.64 | EPS next Y | -6.67 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2025-11-19 07:00 | ROA | -65.81% |
| ROE | — | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 911.33M |
| Shs Float | 7.66M | Short Float | 0.11% | Short Ratio | 1.50 |
| Short Interest | — | 52W High | 20.60 | 52W Low | 0.23 |
| Beta | -2.37 | Avg Volume | 6.36M | Volume | 286.46M |
| Target Price | — | Recom | None | Prev Close | $0.29 |
| Price | $0.36 | Change | 24.16% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
—
Mean price target
2. Current target
$0.36
Latest analyst target
3. DCF / Fair value
$-0.44
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$0.36
Low
—
High
—
Mean
—
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-09-29 | down | HC Wainwright & Co. | Buy → Neutral | — |
| 2025-09-17 | main | HC Wainwright & Co. | Buy → Buy | $35 |
| 2025-09-11 | main | Oppenheimer | Outperform → Outperform | $33 |
| 2025-09-08 | init | Mizuho | — → Outperform | $30 |
| 2025-05-23 | main | HC Wainwright & Co. | Buy → Buy | $12 |
| 2025-04-04 | reit | HC Wainwright & Co. | Buy → Buy | $15 |
| 2025-02-13 | reit | HC Wainwright & Co. | Buy → Buy | $15 |
| 2024-11-15 | reit | HC Wainwright & Co. | Buy → Buy | $15 |
| 2024-08-19 | reit | Oppenheimer | Outperform → Outperform | $15 |
| 2024-05-17 | main | HC Wainwright & Co. | Buy → Buy | $18 |
| 2024-04-02 | main | HC Wainwright & Co. | Buy → Buy | $21 |
| 2024-04-01 | reit | Oppenheimer | Outperform → Outperform | $15 |
| 2023-11-17 | main | HC Wainwright & Co. | Buy → Buy | $22 |
| 2023-08-11 | reit | HC Wainwright & Co. | Buy → Buy | $24 |
| 2023-05-10 | reit | HC Wainwright & Co. | — → Buy | $24 |
| 2023-05-01 | reit | HC Wainwright & Co. | — → Buy | $22 |
| 2023-04-12 | main | HC Wainwright & Co. | — → Buy | $22 |
| 2023-03-27 | reit | HC Wainwright & Co. | — → Buy | $20 |
| 2023-03-06 | main | HC Wainwright & Co. | — → Buy | $20 |
- $180B AI healthcare play: KALA BIO pivots with first agent - Stock Titan Wed, 11 Mar 2026 10
- Why Did KALA Stock Surge 25% Today? - Stocktwits Wed, 11 Mar 2026 17
- KALA BIO Stock Rockets on Plans to Become the ‘Palantir for Biotech’ - TipRanks Wed, 11 Mar 2026 12
- Why Is Kala Bio Stock Soaring Wednesday? - Kala Bio (NASDAQ:KALA) - Benzinga Wed, 11 Mar 2026 12
- What analyst consensus says on KALA stock - Weekly Trend Summary & Long-Term Growth Plans - Naître et grandir Sat, 07 Mar 2026 19
- KALA BIO (KALA) Stock Jumps 70% After Pivoting to AI With ‘Palantir for Biotech’ Vision - CoinCentral Wed, 11 Mar 2026 12
- KALA Stock Crashes 88% in a Month Following Eye Disorder Study Failure - Zacks Investment Research Wed, 08 Oct 2025 07
- Kala Bio Announces Launch Of First Commercial AI Product - marketscreener.com Wed, 11 Mar 2026 13
- Stock Trend Capital Provides Younet AI Investment Update - TMX Newsfile Mon, 09 Mar 2026 10
- Why Did KALA Stock Surge 70% In Pre-Market Today? - Asianet Newsable Wed, 11 Mar 2026 12
- $KALA stock is down 14% today. Here's what we see in our data. | KALA Stock News - Quiver Quantitative Wed, 03 Dec 2025 08
- Kala Bio's CHASE trial misses primary endpoint, KPI-012 development discontinued - Ophthalmology Times Mon, 29 Sep 2025 07
- Younet AI inks exclusive biotech platform deal with KALA BIO - Stock Titan Mon, 09 Mar 2026 10
- How institutional buying supports KALA stock - Quarterly Portfolio Review & Free Risk Controlled Daily Trade Plans - Naître et grandir Sat, 07 Mar 2026 14
- Kala Bio Stock Soars 22% After Hours As Emergency Financing Deal Averts Asset Seizure After Eye Disease Drug Trial Collapse - Stocktwits hu, 05 Mar 2026 19
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 33197 | 27544 | — | Sale at price 0.82 - 0.83 per share. | REUMUTH MARY | Chief Financial Officer | — | 2025-10-23 00:00:00 | D |
| 1 | 154894 | 125464 | — | Sale at price 0.81 per share. | IWICKI MARK T. | Director | — | 2025-10-23 00:00:00 | D |
| 2 | 20806 | 17269 | — | Sale at price 0.83 per share. | KHARABI DARIUS | Officer | — | 2025-10-22 00:00:00 | D |
| 3 | 46748 | 38801 | — | Sale at price 0.83 per share. | BRAZZELL ROMULUS KIM | Officer | — | 2025-10-22 00:00:00 | D |
| 4 | 47768 | 39647 | — | Sale at price 0.83 per share. | BAZEMORE TODD M | Director | — | 2025-10-22 00:00:00 | D |
| 5 | 730408 | 1056722 | — | Sale at price 1.38 - 1.60 per share. | BAKER BROS ADVISORS, L.P. | Former | — | 2025-10-01 00:00:00 | I |
| 6 | 3631 | 14560 | — | Sale at price 4.01 per share. | REUMUTH MARY | Chief Financial Officer | — | 2025-06-24 00:00:00 | D |
| 7 | 4511 | 18089 | — | Sale at price 4.01 per share. | KHARABI DARIUS | Officer | — | 2025-06-24 00:00:00 | D |
| 8 | 13227 | 53040 | — | Sale at price 4.01 per share. | IWICKI MARK T. | Director | — | 2025-06-24 00:00:00 | D |
| 9 | 4058 | 16273 | — | Sale at price 4.01 per share. | BAZEMORE TODD M | Chief Executive Officer | — | 2025-06-24 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -31.92M | -35.57M | -81.08M | -107.04M |
| TotalUnusualItems | -549.00K | -510.00K | 44.06M | -26.21M |
| TotalUnusualItemsExcludingGoodwill | -549.00K | -510.00K | 44.06M | -26.21M |
| NetIncomeFromContinuingOperationNetMinorityInterest | -38.51M | -42.20M | -44.82M | -142.60M |
| ReconciledDepreciation | 259.00K | 303.00K | 537.00K | 975.00K |
| ReconciledCostOfRevenue | 0.00 | 2.56M | 4.10M | |
| EBITDA | -32.47M | -36.08M | -37.02M | -133.25M |
| EBIT | -32.73M | -36.38M | -37.56M | -134.22M |
| NetInterestIncome | -3.73M | -3.10M | -6.60M | -8.28M |
| InterestExpense | 5.78M | 5.81M | 7.27M | 8.38M |
| InterestIncome | 2.06M | 2.71M | 664.00K | 104.00K |
| NormalizedIncome | -37.96M | -41.69M | -88.88M | -116.40M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -38.51M | -42.20M | -44.82M | -142.60M |
| TotalExpenses | 34.23M | 34.33M | 85.25M | 120.67M |
| TotalOperatingIncomeAsReported | -40.98M | -39.66M | -81.71M | -130.25M |
| DilutedAverageShares | 3.80M | 2.43M | 1.52M | 1.32M |
| BasicAverageShares | 3.80M | 2.43M | 1.52M | 1.32M |
| DilutedEPS | -10.15 | -17.35 | -29.48 | -108.32 |
| BasicEPS | -10.15 | -17.35 | -29.48 | -108.32 |
| DilutedNIAvailtoComStockholders | -38.51M | -42.20M | -44.82M | -142.60M |
| NetIncomeCommonStockholders | -38.51M | -42.20M | -44.82M | -142.60M |
| NetIncome | -38.51M | -42.20M | -44.82M | -142.60M |
| NetIncomeIncludingNoncontrollingInterests | -38.51M | -42.20M | -44.82M | -142.60M |
| NetIncomeContinuousOperations | -38.51M | -42.20M | -44.82M | -142.60M |
| PretaxIncome | -38.51M | -42.20M | -44.82M | -142.60M |
| OtherIncomeExpense | -549.00K | -4.77M | 43.14M | -24.90M |
| OtherNonOperatingIncomeExpenses | -4.26M | -926.00K | 1.31M | |
| SpecialIncomeCharges | -549.00K | -510.00K | 44.06M | -26.21M |
| GainOnSaleOfBusiness | 0.00 | 46.99M | 0.00 | |
| OtherSpecialCharges | 2.58M | 32.01M | ||
| RestructuringAndMergernAcquisition | 549.00K | 510.00K | 350.00K | -5.80M |
| NetNonOperatingInterestIncomeExpense | -3.73M | -3.10M | -6.60M | -8.28M |
| InterestExpenseNonOperating | 5.78M | 5.81M | 7.27M | 8.38M |
| InterestIncomeNonOperating | 2.06M | 2.71M | 664.00K | 104.00K |
| OperatingIncome | -34.23M | -34.33M | -81.36M | -109.43M |
| OperatingExpense | 34.23M | 34.33M | 82.69M | 116.58M |
| OtherOperatingExpenses | -6.20M | -4.83M | ||
| ResearchAndDevelopment | 22.09M | 18.59M | 17.65M | 11.52M |
| SellingGeneralAndAdministration | 18.34M | 20.57M | 65.03M | 105.06M |
| GeneralAndAdministrativeExpense | 18.34M | 20.57M | 65.03M | 105.06M |
| OtherGandA | 18.34M | 20.57M | 65.03M | 105.06M |
| GrossProfit | 0.00 | 1.33M | 7.14M | |
| CostOfRevenue | 0.00 | 2.56M | 4.10M | |
| TotalRevenue | 0.00 | 0.00 | 3.89M | 11.24M |
| OperatingRevenue | 0.00 | 0.00 | 3.89M | 11.24M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 6.09M | 2.76M | 1.71M | 1.31M |
| ShareIssued | 6.09M | 2.76M | 1.71M | 1.31M |
| TotalDebt | 32.25M | 36.32M | 42.95M | 80.19M |
| TangibleBookValue | 12.33M | 7.50M | 18.97M | 16.80M |
| InvestedCapital | 42.77M | 41.69M | 61.91M | 95.73M |
| WorkingCapital | 35.84M | 44.52M | 60.26M | 86.94M |
| NetTangibleAssets | 12.33M | 7.50M | 18.97M | 16.80M |
| CapitalLeaseObligations | 1.81M | 2.13M | 13.00K | 1.26M |
| CommonStockEquity | 12.33M | 7.50M | 18.97M | 16.80M |
| TotalCapitalization | 32.43M | 41.69M | 56.91M | 95.73M |
| TotalEquityGrossMinorityInterest | 12.33M | 7.50M | 18.97M | 16.80M |
| StockholdersEquity | 12.33M | 7.50M | 18.97M | 16.80M |
| GainsLossesNotAffectingRetainedEarnings | 0.00 | 0.00 | 0.00 | |
| RetainedEarnings | -667.92M | -629.41M | -587.21M | -542.39M |
| AdditionalPaidInCapital | 680.25M | 636.91M | 606.18M | 559.19M |
| CapitalStock | 6.00K | 3.00K | 2.00K | 1.00K |
| CommonStock | 6.00K | 3.00K | 2.00K | 1.00K |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 43.15M | 48.45M | 67.85M | 122.62M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 26.20M | 40.10M | 42.16M | 85.20M |
| OtherNonCurrentLiabilities | 4.66M | 4.11M | 4.22M | 4.84M |
| NonCurrentDeferredLiabilities | 0.00 | 883.00K | ||
| LongTermDebtAndCapitalLeaseObligation | 21.54M | 35.99M | 37.94M | 79.48M |
| LongTermCapitalLeaseObligation | 1.43M | 1.80M | 0.00 | 548.00K |
| LongTermDebt | 20.10M | 34.19M | 37.94M | 78.93M |
| CurrentLiabilities | 16.96M | 8.35M | 25.68M | 37.42M |
| OtherCurrentLiabilities | 4.15M | 3.82M | ||
| CurrentDeferredLiabilities | 637.00K | 1.07M | 4.78M | 7.01M |
| CurrentDeferredRevenue | 637.00K | 1.07M | 4.19M | 0.00 |
| CurrentDebtAndCapitalLeaseObligation | 10.72M | 334.00K | 5.01M | 711.00K |
| CurrentCapitalLeaseObligation | 380.00K | 334.00K | 13.00K | 711.00K |
| CurrentDebt | 10.34M | 5.00M | ||
| OtherCurrentBorrowings | 10.34M | 5.00M | ||
| PensionandOtherPostRetirementBenefitPlansCurrent | 2.39M | 2.62M | 3.33M | 6.32M |
| CurrentProvisions | 807.00K | 10.30M | ||
| PayablesAndAccruedExpenses | 3.21M | 4.32M | 8.41M | 19.56M |
| CurrentAccruedExpenses | 2.58M | 3.40M | 5.58M | 14.66M |
| Payables | 628.00K | 919.00K | 2.83M | 4.90M |
| AccountsPayable | 628.00K | 919.00K | 2.83M | 4.90M |
| TotalAssets | 55.48M | 55.95M | 86.82M | 139.43M |
| TotalNonCurrentAssets | 2.69M | 3.08M | 878.00K | 15.06M |
| OtherNonCurrentAssets | 246.00K | 301.00K | 462.00K | 11.04M |
| NetPPE | 2.44M | 2.78M | 416.00K | 4.02M |
| AccumulatedDepreciation | -1.31M | -1.11M | -1.22M | -2.86M |
| GrossPPE | 3.75M | 3.89M | 1.64M | 6.88M |
| Leases | 0.00 | |||
| ConstructionInProgress | 0.00 | 100.00K | 0.00 | 1.72M |
| OtherProperties | 1.19M | 894.00K | 391.00K | 2.65M |
| MachineryFurnitureEquipment | 869.00K | 869.00K | 1.23M | 1.22M |
| BuildingsAndImprovements | 1.69M | 2.02M | 16.00K | 1.30M |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 52.80M | 52.87M | 85.94M | 124.37M |
| OtherCurrentAssets | 1.62M | 1.98M | 657.00K | 1.88M |
| AssetsHeldForSaleCurrent | 0.00 | 7.59M | 0.00 | |
| RestrictedCash | 0.00 | 2.04M | ||
| PrepaidAssets | 555.00K | 698.00K | 2.22M | |
| Inventory | 0.00 | 8.64M | ||
| Receivables | 236.00K | 6.50M | 17.45M | |
| OtherReceivables | 119.00K | 908.00K | 2.11M | |
| DuefromRelatedPartiesCurrent | 0.00 | 5.39M | 0.00 | |
| AccountsReceivable | 117.00K | 195.00K | 15.35M | |
| CashCashEquivalentsAndShortTermInvestments | 51.18M | 50.90M | 70.50M | 92.14M |
| OtherShortTermInvestments | 0.00 | |||
| CashAndCashEquivalents | 51.18M | 50.90M | 70.50M | 92.14M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -29.59M | -28.54M | -79.22M | -113.77M |
| RepaymentOfDebt | -5.04M | -10.00M | -40.04M | -78.05M |
| IssuanceOfDebt | 0.00 | 77.78M | ||
| IssuanceOfCapitalStock | 34.96M | 20.50M | 31.80M | 41.23M |
| CapitalExpenditure | -208.00K | -610.00K | -313.00K | -5.54M |
| InterestPaidSupplementalData | 4.61M | 4.62M | 5.96M | 6.84M |
| EndCashPosition | 51.18M | 50.90M | 70.75M | 94.88M |
| BeginningCashPosition | 50.90M | 70.75M | 94.88M | 89.76M |
| ChangesInCash | 286.00K | -19.85M | -24.13M | 5.12M |
| FinancingCashFlow | 29.88M | 8.51M | -7.94M | 42.55M |
| CashFlowFromContinuingFinancingActivities | 29.88M | 8.51M | -7.94M | 42.55M |
| NetOtherFinancingCharges | -119.00K | -2.04M | ||
| ProceedsFromStockOptionExercised | 77.00K | 46.00K | 301.00K | 1.58M |
| NetPreferredStockIssuance | 8.54M | 1.97M | 0.00 | |
| PreferredStockIssuance | 8.54M | 1.97M | 0.00 | |
| NetCommonStockIssuance | 26.43M | 18.54M | 31.80M | 41.23M |
| CommonStockIssuance | 26.43M | 18.54M | 31.80M | 41.23M |
| NetIssuancePaymentsOfDebt | -5.04M | -10.00M | -40.04M | -263.00K |
| NetLongTermDebtIssuance | -5.04M | -10.00M | -40.04M | -263.00K |
| LongTermDebtPayments | -5.04M | -10.00M | -40.04M | -78.05M |
| LongTermDebtIssuance | 0.00 | 77.78M | ||
| InvestingCashFlow | -208.00K | -429.00K | 62.72M | 70.80M |
| CashFlowFromContinuingInvestingActivities | -208.00K | -429.00K | 62.72M | 70.80M |
| NetInvestmentPurchaseAndSale | 0.00 | 134.00K | 8.00K | 76.25M |
| SaleOfInvestment | 0.00 | 10.00M | 5.00M | 76.25M |
| PurchaseOfInvestment | 0.00 | -9.87M | -4.99M | 0.00 |
| NetBusinessPurchaseAndSale | 0.00 | 62.91M | 0.00 | |
| SaleOfBusiness | 0.00 | 62.91M | 0.00 | |
| PurchaseOfBusiness | -4.65M | |||
| NetIntangiblesPurchaseAndSale | 0.00 | -4.65M | ||
| PurchaseOfIntangibles | 0.00 | -4.65M | ||
| NetPPEPurchaseAndSale | -208.00K | -563.00K | -199.00K | -794.00K |
| SaleOfPPE | 0.00 | 47.00K | 114.00K | 92.00K |
| PurchaseOfPPE | -208.00K | -610.00K | -313.00K | -886.00K |
| OperatingCashFlow | -29.38M | -27.93M | -78.91M | -108.23M |
| CashFlowFromContinuingOperatingActivities | -29.38M | -27.93M | -78.91M | -108.23M |
| ChangeInWorkingCapital | -1.78M | 8.89M | 491.00K | -10.62M |
| ChangeInOtherCurrentLiabilities | -319.00K | -13.00K | -344.00K | -689.00K |
| ChangeInOtherCurrentAssets | 0.00 | -144.00K | 0.00 | |
| ChangeInPayablesAndAccruedExpense | -1.82M | -4.33M | -14.00M | 4.95M |
| ChangeInAccruedExpense | -1.53M | -2.42M | -11.93M | 1.71M |
| ChangeInPayable | -291.00K | -1.90M | -2.08M | 3.23M |
| ChangeInAccountPayable | -291.00K | -1.90M | -2.08M | 3.23M |
| ChangeInPrepaidAssets | 359.00K | 5.83M | -2.01M | -2.86M |
| ChangeInInventory | 0.00 | 7.54M | 1.71M | -6.26M |
| ChangeInReceivables | 78.00K | 15.14M | -5.76M | |
| ChangesInAccountReceivables | 78.00K | 15.14M | -5.76M | |
| OtherNonCashItems | 2.26M | -2.39M | 2.29M | 22.53M |
| StockBasedCompensation | 8.39M | 7.46M | 7.01M | 16.09M |
| AmortizationOfSecurities | 22.00K | |||
| DepreciationAmortizationDepletion | 259.00K | 303.00K | 537.00K | 975.00K |
| DepreciationAndAmortization | 259.00K | 303.00K | 537.00K | 975.00K |
| OperatingGainsLosses | -44.41M | 5.39M | ||
| GainLossOnSaleOfBusiness | 0.00 | -46.99M | 0.00 | |
| NetIncomeFromContinuingOperations | -38.51M | -42.20M | -44.82M | -142.60M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for KALA
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|